No evidence was found on the treatment sequences of androgen receptor–targeted agents in patients with castration-sensitive prostate cancer.
Evidence from retrospective studies, including those within a systematic review, suggests that sequential treatment of abiraterone followed by enzalutamide is more favourable than enzalutamide followed by abiraterone in improving clinical outcomes such as response rate and progression-free survival, but not overall survival, in patients with castration-resistant prostate cancer.
Evidence from a retrospective study suggests that docetaxel-containing treatment sequences with androgen receptor–targeted agents may improve progression-free survival compared to sequential therapy with androgen receptor–targeted agents alone in patients with castration-resistant prostate cancer.
Evidence from a retrospective study did not reveal differences in clinical outcomes of patients with castration-resistant prostate cancer treated with sequential androgen receptor–targeted agents with or without interposed chemotherapy or radium-223.
These findings were in line with those observed in a 2019 CADTH report.1 However, the findings should be interpreted with caution due to low-quality evidence.
No comparative cost-effectiveness studies were identified.
MP52-10 OPTIMAL SEQUENCING STRATEGY USING DOCETAXEL AND ANDROGEN RECEPTOR AXIS-TARGETED AGENTS IN PATIENTS WITH CASTRATION-RESISTANT PROSTATE CANCER: UTILIZATION OF NEUTROPHIL-TO-LYMPHOCYTE RATIO
